Mad Hedge Technology Letter
August 18, 2021
Fiat Lux
Featured Trade:
(WILL THE ARK INNOVATION FUND CRASH?)
(ARKK), (TSLA)
Mad Hedge Technology Letter
August 18, 2021
Fiat Lux
Featured Trade:
(WILL THE ARK INNOVATION FUND CRASH?)
(ARKK), (TSLA)
Michael Burry, the audacious hedge-fund icon who is famous for being represented in the movie “The Big Short,” is aggressively taking the other side of Cathy Woods, a name synonymous with tech growth.
Such prominent names at loggerheads with each other signals a divergence in interest rate expectations and the fallout, or lack of it, for tech growth stocks.
That is fundamentally the crux of the issue, with the stock market levered so heavily that even a quarter rate rise would undermine it.
Woods seems to minimize any ill-effects that broader volatile behavior will have on her niche area of the tech market.
Statistically speaking, growth tech outperforms the broader market when already low-interest rates are expected to trend lower.
The inverse holds true when interest rates are expected to rise, then tech growth stocks will underperform the broader market and even non-growth tech.
This is precisely why in 2020, elevated growth names rode the wave of the pandemic and shelter-at-home trade as the Fed lowered rates to fuel the stock appreciation.
The party is somewhat over now; or at least the low-hanging fruit has been plucked.
Burry disclosed that his firm, Scion Asset Management, held bearish put options against 235,500 shares of Woods’ actively managed ARK Innovation exchange-traded fund (ARKK) at the end of the second quarter.
The new position was valued at almost $31 million, according to the quarterly filing, which is required for hedge funds above a certain size.
Burry also has a growing put position worth $731 million in Tesla (TSLA), which remains Wood's highest conviction stock.
Woods responded saying, “I do not believe that he understands the fundamentals that are creating explosive growth and investment opportunities in the innovation space.”
Woods doesn’t understand that this isn’t a call based on a long-term forecast of growth tech outperforming the broader market but more of a short-term call that even slightly rising interest rates will penalize high beta names more than the rest.
No doubt that Burry has a clearly defined entry and exit point while Woods seems to be in the business of blanket statements disregarding idiosyncratic particulars which is a dangerous game.
There is the premise out there that a slightly rising interest rate will rotate money back into FANG names who can, by and large, stomach the ensuing bond rise opposed to loss-making growth stocks that depend on cheap money to fuel unproven business models.
Last year was sensational for ARK Invest, there is no point to play this down, it raked in billions of new assets from spectacular performances by Wood’s active ETFs focused on high-growth innovation-driven stocks. Several were among 2020’s best-performing funds, with returns of more than 100%.
But the funds have struggled to maintain that momentum this year. Many of their stock holdings are trading at frothy valuations that are betting on outperforming expected growth in the future.
As inflation flares up and interest rates rise, the current value of the growth companies’ future cash flow diminishes.
The ARK Innovation ETF is now 6% down for the year, with $500 million asset outflows in the past month.
Burry hasn’t been always right such as pulling out of GameStop (GME) in 2020 before the frenzied buying, which left a 2,000% surge on the table.
Wood also told us that Burry may not understand the current growth environment, as inflationary pressures are likely to be short-term in nature.
"Most bears seem to believe that inflation will continue to accelerate, shortening investment time horizons and destroying valuations," Wood explained. But Wood thinks supply-chain-related issues will be resolved, helping relieve inflationary pressures.
Wood pointed to a sharp drop in certain commodity prices in recent weeks (including lumber, copper, and oil) in regards to explaining why inflation may not linger for as long as some think. Used-car prices are also beginning to fall after an extraordinary rise, and a strengthening US dollar has also put pressure on commodity prices, according to Wood.
Nevertheless, Woods fails to chime in on China closing one of its biggest ports or Southeast Asian manufacturing hubs like Vietnam, Thailand effectively being shutdown from the delta virus.
Ultimately, Woods offers an overly blasé attitude towards an extremely niche problem. It is almost as if she would say the same thing no matter what condition the broader market is in.
And while cheerleading the stocks you are invested in is not a criminal act, to completely miss that Burry most likely has a different timeline than Woods shows that she has tunnel vision in terms of the phase of the economic cycle we are in.
I would say with conviction that it’s normal for Tesla to retrace after a 600% move up in 2020. There is nothing wrong with it and I see it as healthy market behavior.
Burry is essentially betting on a revision to the mean, which is high risk, ostensibly, Tesla most likely won’t rise another 600% in 2021 as well which is where Burry comes in.
I won’t sit here and advocate to market time mean revisions of tech growth stocks as we are not in that business, but this little skirmish screams to jump back into best-of-breed tech stocks to protect ourselves at frothy levels.
Mad Hedge Biotech & Healthcare Letter
June 22, 2021
Fiat Lux
FEATURED TRADE:
(PRIMED FOR DOMINANCE)
(TDOC), (AMZN), (AMWL), (WMT), (CVS), (ARKK), (TSLA)
While growth stocks have already begun clawing their way back following the losses they suffered earlier this year, there are still former market favorites struggling to bounce back.
One of them is Teladoc Health (TDOC).
To date, Teladoc is still trading at roughly 40% below its previous highs.
While this can be frustrating for its investors, the current situation might just be an opportune time to add this stock to your portfolio.
Teladoc emerged as the leader in virtual care in 2020 by being at the right place at the right time when the pandemic struck. That year, the company’s revenue rose by a whopping 145% compared to its 2019 performance.
These days though, the stock has lost half of its value. Although that’s definitely a head-scratcher, Teladoc’s 51.5 million paid memberships in the United States alone still make it the most dominant force in this industry.
For a long-term investor, the situation presents a compelling opportunity.
Teladoc is a growing business that’s expanding both in the US and globally. While penetrating more markets would happen over time, the basic footprint has been established. This offers Teladoc much-needed exposure to a massive addressable market.
The global market for telemedicine is estimated to expand from $49.9 billion in 2019 to a jaw-dropping $459.8 billion by 2030.
In North America, which holds roughly 34.4% of the market share in 2020, the telemedicine market generated $19.23 billion during the pandemic.
Taking into consideration Teladoc’s revenue of $967.4 million for its US segments in 2020, it becomes clear that the company is only getting started, as this comprised only 5% of the market size.
If the company maintains its momentum, then the next 10 years would be an incredible journey for Teladoc investors.
Despite the disappointing share price performance of Teladoc in the past months, the company’s actual business has sustained its growth.
Revenue continues to rapidly rise, showing off a 151% growth in the first quarter of 2021.
This impressive growth has prompted Teladoc to boost its full-year revenue guidance to $2 billion, which indicates an 80% year-over-year gain.
Impressive growth has been observed all around, with access fee revenue going up 183% while visit fees climbed 24%.
Considering the size of the market, it no longer comes as a surprise that Teladoc is facing competitive threats.
Amazon (AMZN) and Amwell (AMWL) have recently entered the virtual care market. Even Walmart (WMT) and CVS (CVS) have been working on toppling Teladoc as well.
Despite the competition, Teladoc remains ahead of the pact thanks to its continuous efforts to innovate.
For example, the latest innovation from Teladoc is Primary360.
This product is designed to take virtual healthcare to the next level. It offers personalized service at the patient level. Here’s a preview of how it works.
Traditionally, patients go to their doctors when they discover a health problem. This is a reactive way of dealing with health. In contrast, Primary360 is proactive.
That is, the product monitors the patients individually from annual checkups to ongoing treatments to manage chronic conditions. Through closely monitoring the patients, Teladoc is able to perform earlier diagnoses of potential diseases and help doctors reach better outcomes for treatments.
To better picture the long-term rewards of this company, it’s good to keep in mind that Teladoc is actually the second biggest holding of Cathie Wood’s ARK Innovation ETF (ARKK), next only to Tesla (TSLA).
Teladoc Health emerged as one of the most popular pandemic plays in 2020.
While the stock tumbled when vaccines hit the market, its projected growth trajectory remains promising. In fact, Teladoc’s revenue growth is anticipated to skyrocket over the remainder of this decade, with telemedicine estimated to reach roughly half a trillion dollars by 2030.
For investors on the lookout for long-term plays, Teladoc Health's tumble has presented a good opportunity to add it to your portfolio.
Global Market Comments
May 14, 2021
Fiat Lux
Featured Trade:
(MAY 12 BIWEEKLY STRATEGY WEBINAR Q&A),
(FCX), (QQQ), (JWN), (DAL), (MSFT), (PLTR), (V), (MA), (AXP), (UUP), (FXA), (SPWR), (FSLR), (TSLA), (ARKK), (CLX), (NIO), (EPEV), (SOX), (VIX), (USO), (XLE)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds: